The impact of COVID-19 on the diagnosis and treatment of HCC: analysis of a nationwide registry for advanced liver diseases (REAL)

• Published in: Scientific reports Vol. 14; no. 1; p. 2826
• Main Authors: Okushin, Kazuya, Tateishi, Ryosuke, Hirakawa, Shinya, Tachimori, Hisateru, Uchino, Koji, Nakagomi, Ryo, Yamada, Tomoharu, Nakatsuka, Takuma, Minami, Tatsuya, Sato, Masaya, Fujishiro, Mitsuhiro, Hasegawa, Kiyoshi, Eguchi, Yuichiro, Kanto, Tatsuya, Yoshiji, Hitoshi, Izumi, Namiki, Kudo, Masatoshi, Koike, Kazuhiko
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 03.02.2024; Nature Publishing Group; Nature Portfolio
• Subjects: 692/308/174; 692/4020/4021; Carcinoma, Hepatocellular - diagnosis; Carcinoma, Hepatocellular - epidemiology; Carcinoma, Hepatocellular - therapy; Coronaviruses; COVID-19; COVID-19 - complications; COVID-19 - diagnosis; COVID-19 - epidemiology; COVID-19 Testing; Etiology; Hepatocellular carcinoma; Humanities and Social Sciences; Humans; Liver cancer; Liver diseases; Liver Neoplasms - diagnosis; Liver Neoplasms - epidemiology; Liver Neoplasms - therapy; multidisciplinary; Pandemics; Patients; Registries; Science; Science (multidisciplinary); Tumors; Japan
• ISSN: 2045-2322; 2045-2322
• DOI: 10.1038/s41598-024-53199-6

The number of cancer cases diagnosed during the coronavirus disease 2019 (COVID-19) pandemic has decreased. This study investigated the impact of the pandemic on the clinical practice of hepatocellular carcinoma (HCC) using a novel nationwide REgistry for Advanced Liver diseases (REAL) in Japan. We retrieved data of patients initially diagnosed with HCC between January 2018 and December 2021. We adopted tumor size as the primary outcome measure and compared it between the pre-COVID-19 (2018 and 2019) and COVID-19 eras (2020 and 2021). We analyzed 13,777 patients initially diagnosed with HCC (8074 in the pre-COVID-19 era and 5703 in the COVID-19 era). The size of the maximal intrahepatic tumor did not change between the two periods (mean [SD] = 4.3 [3.6] cm and 4.4 [3.6] cm), whereas the proportion of patients with a single tumor increased slightly from 72.0 to 74.3%. HCC was diagnosed at a similar Barcelona Clinic Liver Cancer stage. However, the proportion of patients treated with systemic therapy has increased from 5.4 to 8.9%. The proportion of patients with a non-viral etiology significantly increased from 55.3 to 60.4%. Although the tumor size was significantly different among the etiologies, the subgroup analysis showed that the tumor size did not change after stratification by etiology. In conclusion, the characteristics of initially diagnosed HCC remained unchanged during the COVID-19 pandemic in Japan, regardless of differences in etiology. A robust surveillance system should be established particularly for non-B, non-C etiology to detect HCC in earlier stages.